Patients with early-stage low rectal tumours, without any adverse features, amenable to local excision or transanal endoscopic microsurgery should undergo the procedure without neoadjuvant treatment. If histopathology confirms the full excision and initial low risk preoperative staging, there is no indication for further treatment, and this approach provides excellent oncological and functional outcomes. However, when high risk features are present, such as third submucosal layer (sm3) invasion, positive margin, grade 3, lymphovascular invasion, tumour budding or mucinous subtype, and in cases of pT2 tumours, local resection alone is not sufficient. Local and/or regional recurrences can be seen in as much as 20% of cases [
11]. The standard treatment for completion is radical resection, and since the tumours are low, in the majority of cases it results in a permanent stoma. In the context of organ preservation, only few studies have included patients with early-stage tumours. Habr-Gama et al. did a retrospective study assessing the outcomes of a W&W strategy on patients with cT2N0 rectal adenocarcinoma, less than 7 cm from the anal verge, following two different regimen of nCRT [
12•]. Patients in the ‘extended’ CRT group (54Gy of radiation and 6 cycles of 5-fluorouracil (5FU)-based chemotherapy) were more likely to achieve a cCR compared to the standard group (50.4 Gy and 2 cycles of 5FU-based chemotherapy) (85.7 vs 56.6%,
p < 0.001). As mentioned above, in the initial study by Habr-Gama [
10], the rate of cCR was 26.8% for the entire cohort, which comprised T3 tumours in 69% of cases. Therefore, achieving a rate of cCR of 85%, or even 56% with a standard regimen of nCRT, is impressive and suggests the potential of early tumours for W&W. Similarly, an Italian group of investigators have cumulated several years of experience in organ preservation in early-stage low rectal cancers. They have reported in 2012 the results of a prospective randomised clinical trial comparing endoluminal locoregional resection (ELRR) with laparoscopic total mesorectal excision (TME) for early-stage cancers following nCRT [
13]. Eligible patients had clinically staged T2N0M0 disease (staging modalities including endorectal ultrasonography, sigmoidoscopy with biopsies, pelvic MRI and whole-body CT), located within 6 cm of the anal verge, grade 1 or 2 tumours with a diameter of less than 3 cm. Patients with lymphovascular or perineural invasion were excluded. The patients in the study received upfront nCRT (50.4 Gy in 5 weeks with concomitant 5FU), had restaging investigations 6 weeks after treatment and were then randomised between ELRR and TME. With a median follow-up of 9.6 years, there was no statistically significant difference between the two groups with regards to locoregional recurrences, rate of distant metastases, cancer-specific survival, disease-free survival and overall survival. The rate of pCR with nCRT was approximately 27% (28% in ELRR group, 26% in TME group). Other studies investigated local excision following nCRT in early-stage low rectal cancer and reported higher rates of pCR (49–59%) [
14•,
15,
16]. All these studies provide interesting data in favour of nCRT followed by surveillance or local resection in patients with early-stage low cancers, suggesting that these patients might actually be ideal candidates for organ preservation. However, they involve a relatively small number of patients. The STAR-TREC trial (NCT02945566) is ongoing and should help clarify the question. Although promising, this subject raises an ethical issue. Unless there is a threatened surgical resection margin, which is considered as a high risk feature, patients with early-stage rectal cancer are not typically considered for neoadjuvant treatment. Offering upfront CRT to these patients, the decision based purely on clinical staging, is risky. At our institution, the initial staging of early low rectal cancer includes a high-resolution pelvic MRI amongst other standard investigations. The results are discussed in our weekly multidisciplinary meeting where images are reviewed and management options discussed. When the CRM is clear and the tumour amenable to local resection, we tend to favour this approach as first-line intervention and rediscuss the case with the final histopathology report. It has the advantage of providing accurate pathological staging on which to base future management decisions. When further treatment is recommended, we favour discussion with the patients regarding completion radical surgery versus CRT in an attempt at organ preservation with close imaging and clinical surveillance, knowing that the latter is not yet standard. Although we have reported previously on the good oncological outcomes of patients who decline surgery and undergo adjuvant CRT [
17], we prefer, if available, participation in research trials.